Erudio Healtherudio.com
Indication
Neuroendocrine carcinoma
1 HCP commentary report on clinical trials in Neuroendocrine carcinoma. Each report covers what clinicians said in public about one trial, with the source behind every view.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| DAREON-NEC-1 NCT07544654 · Boehringer Ingelheim | first-line DLL3-positive advanced extrapulmonary neuroendocrine carcinomas | Phase 3 | 58 | 6 | Focused | Nov 15, 2026 | Preview |